RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving combination chemotherapy together with or without bevacizumab is more effective in treating patients with nonmetastatic breast cancer.. PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy works compared with giving combination chemotherapy together with bevacizumab in treating patients with nonmetastatic breast cancer. ...
TY - JOUR. T1 - Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer. T2 - Results of International Breast Cancer Study Group trial 15-95. AU - Basser, Russell L.. AU - ONeil, Anne. AU - Martinelli, Giovanni. AU - Green, Michael D.. AU - Peccatori, Fedro. AU - Cinieri, Severio. AU - Caotes, Alan S.. AU - Gelber, Richard D.. AU - Aebi, Stefan. AU - Castiglione-Gertsch, Monica. AU - Viale, Guiseppe. AU - Price, Karen N.. AU - Goldhirsch, Aron. PY - 2006/1/20. Y1 - 2006/1/20. N2 - Purpose: To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes. Patients and Methods: Three hundred ...
Background: Young breast cancer occupies a higher and higher proportion of breast cancer, especially in Asia, and is associated with a more unfavorable prognosis compared with the disease arising in older women. However, the poor prognosis of young breast cancer cannot be fully explained by the clinical and molecular factors. Methods: This study investigated 1125 Chinese breast cancer patients diagnosed from 2009 to 2013. A data mining of gene expression profiles was performed for the young and older breast cancer patients, identifying significantly differentially expressed genes. Quantitative RT-PCR, Western blotting and immunohistochemistry assay were carried out for the clinical sample validations. Results: The investigation firstly displayed that young patients (≤45 years) accounted for 47.6 % (535/1125) of breast cancer, and clinically associated with some unfavorable factors related to poor prognosis, such as invasive pathological type, high tumor grade, lymph node positive, ER ...
Clinical trial for Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Stage II Breast Cancer | Triple Negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | Stage IA Breast Cancer , MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
How long do people usually live with untreated breast cancer - How long do people usually live with untreated breast cancer? Variable. This is highly dependent on the cancer type and stage of presentation. Some aggressive forms of cancer may take over vital organs within months; other breast cancers may rarely spread to other organs and may be indolent for years and years. What remains true is that there is no benefit of watchful waiting when it comes to breast cancer: all else being equal, early diagnosis can save lives.
Title:Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66. VOLUME: 13 ISSUE: 3. Author(s):Leila Farahmand, Sepideh Mansouri, Narges Jafarbeik-Iravani, Azin Teymourzadeh and Keivan Majidzadeh-A*. Affiliation:Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran. Keywords:Alternative growth cascades, breast cancer, receptor tyrosine kinases, signaling pathways, stemness phenotype, tamoxifen resistance.. Abstract:Background: Tamoxifen is widely administered ...
Despite progress in the management of breast cancer, the molecular underpinnings of clinically aggressive subtypes of the disease are not well-understood. Here, we show that activation of Notch developmental signaling in estrogen receptor (ER)-negative breast cancer cells results in direct transcriptional up-regulation of the apoptosis inhibitor and cell cycle regulator survivin. This response is associated with increased expression of survivin at mitosis, enhanced cell proliferation, and heightened viability at cell division. Conversely, targeting Notch signaling with a peptidyl gamma-secretase inhibitor suppressed survivin levels, induced apoptosis, abolished colony formation in soft agar, and inhibited localized and metastatic tumor growth in mice, without organ or systemic toxicity. In contrast, ER+ breast cancer cells, or various normal cell types, were insensitive to Notch stimulation. Therefore, ER- breast cancer cells become dependent on Notch-survivin signaling for their maintenance, in vivo.
TY - JOUR. T1 - Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer. AU - Wasif, Nabil. AU - Neville, Matthew. AU - Gray, Richard. AU - Cronin, Patricia. AU - Pockaj, Barbara A. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. Study Design: The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: ...
Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P,5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P,0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and ...
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.s profile, publications, research topics, and co-authors
The Ets-1 transcription factor is a candidate breast cancer oncogene that regulates the expression of genes involved in tumor progression and metastasis. Ets-1 signaling has also been linked to the development of a basal-like breast cancer phenotype. We recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Thus, we examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells. Promoter region analyses were performed on genes upregulated in inducible nitric oxide synthase (NOS2) high expressing tumors for Ets-binding sites. In vitro mechanisms were examined in human basal-like breast cancer cells lines. NO signaling effects were studied using either forced NOS2 expression or the use of a chemical NO-donor, diethlylenetriamine NONOate (DETANO). Promoter region analysis of genes that are up-regulated in
Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies). Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes. Historically, breast cancer was treated with radical surgery alone. Advances in the understanding of the natural course of breast cancer as well as the development of systemic therapies allowed for the use of breast-conserving surgeries, however, the nomenclature of viewing non-surgical management from the viewpoint of the definitive surgery lends to two adjectives connected with treatment timelines: adjuvant (after surgery) and neoadjuvant (before surgery). The mainstay ...
Breast cancer is considered as a fatal disease and it is known to be the number one cause of cancer fatality in women. According to American cancer society, an estimated 1.3 million new breast cancer instances are detected every year which includes 465,000 deaths. In order to productively tackle this devastating disease, we must push innovative scientists to research cancer at its most basic stage. In other words, breast cancer research work should be done at its molecular stage. Also, besides the governments, private organizations must offer flexible budget to scientists who will be doing breast cancer research work.. Proper financial support of breast cancer investigation projects; can not only lead to better prevention methods but it can also assist towards earlier detection techniques and new anticancer drugs and cure.. Not so long ago, scientists who are working towards breast cancer research project, have created and successfully tested a breast cancer vaccine which is possibly to cure ...
Purpose: Mammographic density is one of the strongest risk factors for breast cancer. However, very little is known about how other breast cancer risk factors may modify the association between breast density and breast cancer. We investigated if associations of breast density and breast cancer differ according to the level of other known breast cancer risk factors.. Methods: This study included 1,044 incident breast cancer cases diagnosed within the Nurses Health Study cohort and 1,794 matched controls. Percent breast density, absolute dense and non-dense areas were measured from digitized film images with computer-assisted methods. Information on breast cancer risk factors was obtained prospectively from biennial questionnaires completed before the date of the cancer diagnosis for cancer cases and their matched controls. We used multivariate logistic regression to describe the association between breast density measures and breast cancer risk. The risk estimates were presented as odds ratios ...
TY - JOUR. T1 - External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. AU - van de Water, Willemien. AU - Kiderlen, Mandy. AU - Bastiaannet, Esther. AU - Siesling, Sabine. AU - Westendorp, Rudi G.J.. AU - van de Velde, Cornelis J.H.. AU - Nortier, Johan W.R.. AU - Seynaeve, Caroline. AU - de Craen, Anton J.M.. AU - Liefers, Gerrit-Jan. PY - 2014. Y1 - 2014. N2 - Background: Inclusion in trials is selective, and thus results may not be generalizable to the general population. The aim of this study was to investigate the external validity of randomized clinical trial outcomes for elderly breast cancer patients.Methods: We compared characteristics and outcomes of breast cancer patients (n = 1325) who participated in a randomized clinical trial (Tamoxifen Exemestane Adjuvant Multinational trial) with unselected breast cancer patients of corresponding age from the general population (n = 1056). Dutch patients aged 65 years or older at diagnosis of ...
NBCC believes that research is the best weapon we have to end breast cancer and recognizes that the financial resources available to complete this task are not infinite. Therefore, it is critical that breast cancer research be as effective as possible. NBCC is dedicated to increasing the effectiveness of breast cancer research by collaborating with investigators and involving knowledgeable breast cancer advocates in all aspects of research design and oversight. NBCC has also made strides towards improving the effectiveness of breast cancer research by bringing together leading thinkers from many fields to create innovative research strategies and pioneer new research models. As a result of these experiences, NBCC has determined that certain values facilitate progress toward ending breast cancer.. Breast cancer research takes place within many disciplines, including, among others, basic science, clinical research, epidemiology, social sciences, and health services research. Generally, research ...
Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated. The purpose of classification is to select the best treatment. The effectiveness of a specific treatment is demonstrated for a specific breast cancer (usually by randomized, controlled trials). That treatment may not be effective in a different breast cancer. Some breast cancers are aggressive and life-threatening, and must be treated with aggressive treatments that have major adverse effects. Other breast cancers are less aggressive and can be treated with less aggressive treatments, such as lumpectomy. Treatment algorithms rely on breast cancer classification to define specific subgroups that are each treated according to the best ...
Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously
The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. ...
Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor α and Suppresses Human Breast Cancer Cell Proliferation. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
More than two million American women are breast cancer survivors. Approximately one-third of these women are premenopausal at diagnosis and face issues related to reproduction as they undergo cancer treatment. Ovarian function after breast cancer diagnosis has implications on breast cancer prognosis, choice of adjuvant therapy and reproductive issues such as desire for fertility or concerns about menopause. Therefore, tools to accurately predict ovarian function in breast cancer survivors could significantly impact physicians and patients in counseling, medical and surgical treatment choices, and consideration of fertility preservation options.. The goal of this proposal is to identify pre-chemotherapy hormonal, genetic and ovarian imaging markers that can predict ovarian failure and characterize the course of ovarian function after chemotherapy. The investigators plan to follow a group of young women from breast cancer diagnosis to five years after chemotherapy. The investigators will study the ...
Even luminal A tumors - normally considered the easiest breast cancer tumors for doctors to eradicate and for the patient to survive - can still cause death a decade after they are found through cancer marker lab testing.. These findings, appearing in the journal Cancer Epidemiology, Biomarkers and Prevention, were compiled over the course of 21 years of monitoring 1,000 breast cancer patients at Kaiser Permanente Southern California.. It is important to consider breast cancer molecular subtypes in determining the optimal treatment for women with breast cancer. Women with luminal A tumors - the least aggressive but most common cancerous breast tumor - could benefit from extended treatment, said Reina Haque, lead study author from the Kaiser Permanente Southern California Department of Research and Evaluation.. Nonetheless, breast cancer patients have a high likelihood of surviving luminal A tumors, compared to the four other types of breast cancer listed by the Kaiser researchers. The Centers ...
Kellie Martens, M.A., a doctoral student at the University of Colorado Denver, works with Dr. Kristin Kilbourn in the field of psycho-oncology. She is interested in learning what influences quality of life in young breast cancer survivors, with the intention of designing support groups or ways of screening that might make adjusting to a breast cancer diagnosis less difficult for young women. Please refer to the flyers (below) for more information. Its easy to participate, as women must only complete an on-line survey (IRB approved). ...
TY - JOUR. T1 - Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. AU - Munzone, Elisabetta. AU - Gray, Kathryn P.. AU - Fumagalli, Caterina. AU - Guerini-Rocco, Elena. AU - Láng, István. AU - Ruhstaller, Thomas. AU - Gianni, Lorenzo. AU - Kammler, Roswitha. AU - Viale, Giuseppe. AU - Di Leo, Angelo. AU - Coates, Alan S.. AU - Gelber, Richard D.. AU - Regan, Meredith M.. AU - Goldhirsch, Aron. AU - Barberis, Massimo. AU - Colleoni, Marco. PY - 2018/7/1. Y1 - 2018/7/1. N2 - Purpose: We investigated the occurrence and the prognostic and predictive relationship of a selected number of somatic mutations in triple-negative breast cancer (TNBC) patients having known clinical outcomes treated within the IBCSG Trial 22-00. Methods: A matched case-control sampling selected patients enrolled in the IBCSG Trial 22-00 who had TNBC tumors, based on local assessment. Cases had invasive breast cancer recurrence (at local, regional, or ...
BioAssay record AID 103718 submitted by ChEMBL: In vitro cytotoxicity against human breast carcinoma cell line MCF-7 at 8.1*10e-5M.
A receptor blotting technique was used to detect SH2 domain containing epidermal growth factor receptor (EGFR) substrates that exhibited differential expression either between normal breast epithelial cells and breast cancer cells or between different human breast cancer cell lines. This identified a 25 kD protein, subsequently identified as Grb2, which was markedly overexpressed in three breast cancer cell lines (MCF-7, MDA-MB-361 and -453) relative to both normal breast epithelial cells and the majority of breast cancer cell lines. Northern blot analysis revealed that 7/19 breast cancer cell lines exhibited more than twofold overexpression of Grb2 mRNA, with overexpression correlating with high expression of erbB receptors. In MCF-7, MDA-MB-361 and -453 cells the overexpression of Grb2 mRNA and protein was accompanied by a small amplification of the Grb2 gene locus. Overexpression of Grb2 correlated with increased complex formation between Grb2 and the hSos-1 Ras GDP-GTP exchange protein. This
This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam
Operable breast cancer patients may experience late recurrences because of reactivation of dormant tumor cells within the bone marrow (BM). Identification of patients who would benefit from extended therapy is therefore needed. BM samples obtained pre- and post-surgery were previously analysed for presence of disseminated tumor cells (DTC) by a multimarker mRNA quantitative reverse-transcription PCR assay. Updated survival analyses were performed on all patient data (n = 191) and in a subgroup of patients alive and recurrence-free after 5 years (n = 156). DTC data were compared to the mitotic activity index (MAI) of the primary tumors. Median follow-up time was 15.3 years. Among the 191 patients, 49 (25.65%) experienced systemic relapse, 24 (49%) within 5-18 years after surgery. MAI and pre- and post-operative DTC status had significant prognostic value based on Kaplan-Meier analyses and multiple Cox regression in the overall patient cohort. With exclusion of patients who relapsed or died within 5 years
We undertook this study to determine whether women with increased breast density had a greater likelihood of developing invasive breast cancer following lumpectomy for DCIS when compared to women with lower breast density, adjusting for age and radiation treatment. Our findings support the only previous report examining the association between breast density and DCIS recurrence, which suggested that the rate of second breast events following a diagnosis of DCIS may be increased in women with high breast density (33). In this previous study, breast density was measured as a continuous variable which was then categorized into four breast density groups. The number or events was comparable to the current study, with 91 ipsilateral events and 28 contralateral events. When compared with the lowest density group (,25% dense), the highest density group (≥75% dense) had an adjusted relative risk of 3.2 [95% confidence interval (95% CI), 1.2-8.5] for any invasive cancer. In comparison, although we ...
Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, and in some cases, may necessitate a change in treatment plan.
...Many breast cancer patients are treated with a drug called tamoxifen. ... Resistances to drugs are the main reason why therapies fail and disea...By treating breast cancer cells in vitro with regular doses of tamoxif...If microRNA 375 levels are low breast cancer cells increase the produ...,MicroRNA,controls,malignancy,and,resistance,of,breast,cancer,cells,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
TY - JOUR. T1 - Association analysis identifies 65 new breast cancer risk loci. AU - Michailidou, Kyriaki. AU - Lindström, Sara. AU - Dennis, Joe. AU - Beesley, Jonathan. AU - Hui, Shirley. AU - Kar, Siddhartha. AU - Lemaçon, Audrey. AU - Soucy, Penny. AU - Glubb, Dylan. AU - Rostamianfar, Asha. AU - Bolla, Manjeet K. AU - Wang, Qin. AU - Tyrer, Jonathan. AU - Dicks, Ed. AU - Lee, Andrew. AU - Wang, Zhaoming. AU - Allen, Jamie. AU - Keeman, Renske. AU - Eilber, Ursula. AU - French, Juliet D. AU - Qing Chen, Xiao. AU - Fachal, Laura. AU - McCue, Karen. AU - McCart Reed, Amy E. AU - Ghoussaini, Maya. AU - Carroll, Jason S. AU - Jiang, Xia. AU - Finucane, Hilary. AU - Adams, Marcia. AU - Adank, Muriel A. AU - Ahsan, Habibul. AU - Aittomäki, Kristiina. AU - Anton-Culver, Hoda. AU - Antonenkova, Natalia N. AU - Arndt, Volker. AU - Aronson, Kristan J. AU - Arun, Banu. AU - Auer, Paul L. AU - Bacot, François. AU - Barrdahl, Myrto. AU - Baynes, Caroline. AU - Beckmann, Matthias W. AU - Behrens, ...
TY - JOUR. T1 - Reclaiming life on ones own terms. T2 - A grounded theory study of the process of breast cancer survivorship. AU - Sherman, Deborah Witt. AU - Rosedale, Mary. AU - Haber, Judith. PY - 2012/5. Y1 - 2012/5. N2 - Purpose/Objectives: To develop a substantive theory of the process of breast cancer survivorship. Research Approach: Grounded theory. Setting: A LISTSERV announcement posted on the SHARE Web site and purposeful recruitment of women known to be diagnosed and treated for breast cancer. Participants: 15 women diagnosed with early-stage breast cancer. Methodologic Approach: Constant comparative analysis. Main Research Variables: Breast cancer survivorship. Findings: The core variable identified was Reclaiming Life on Ones Own Terms. The perceptions and experiences of the participants revealed overall that the diagnosis of breast cancer was a turning point in life and the stimulus for change. That was followed by the recognition of breast cancer as now being a part of life, ...
Dent et al 20 showed that patients with Triple negative breast cancer has less lymph node metastases but is more aggressively. It may be due to hematogenous spread or lack of targetable treatment. Chengshuai Si et al 21 study showed that tumor size and tumor subtype show statistical significance with LN involvement. Luminal B type showed significant higher probability of LN involvement, Triple positive and triple negative breast cancer accounts the most and least possibility of LN involvement.. Emi Yoshihara et alHYPERLINK https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589678/ l R3″22 study showed that the incidence of ALNM was significantly associated with the presence of LVI (P,0.001), larger tumour size (P , 0.001), higher histologic grade (P , 0.001) and no effect of age. Elsayed M Ali1 et al23study evaluated 258 patients with invasive breast carcinomas, ER and PR expression were demonstrated in 78.7% and 76.4%, respectively and over-expression of HER-2/neu was detected in 13.2% of ...
TAMPA, Fla. - Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patients own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease. The HER2 protein is overexpressed in nearly 25 percent of all breast cancer tumors and is associated with aggressive disease and poor prognosis. Moffitt researchers, led by physician-scientist Brian J. Czerniecki, M.D., Ph.D., have previously shown that immune cells are less able to recognize and target cancer cells that express HER2 as breast cancer progresses into a more advanced and invasive stage. This suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.. The researcher team developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells. Their approach ...
Health, ...A gene target for drug resistance a triple-drug cocktail for triple n...SIMPLE FINGERTIP TEST MAY IDENTIFY BREAST CANCER PATIENTS AT RISK FOR ...CTS most often associated with computer keyboard typing is caused by...For the study researchers gathered and analyzed information on 104 wo...,Simple,fingertip,test,may,identify,breast,cancer,patients,at,risk,for,carpal,tunnel,syndrome,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null ...
These new funds bring Susan G. Komens total breast cancer research investment to more than $1 billion since its inception in 1982, and investment in research focused on metastatic breast cancer to $210 million. Next to the U.S. government, Susan G. Komen is the largest nonprofit funder of breast cancer research in the world, and much of that investment has been awarded to scientists and research institutions in San Diego. As a local office, Susan G. Komen San Diego has invested more than $19 million in global breast cancer research and local breast health services since our inception in 1995.. In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer, said George Sledge, Susan G. Komens Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.. Metastatic (stage iv) breast cancer is the most advanced stage of breast cancer, which does not yet have a ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before.. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time.. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases. There are two main reasons this number is so large and ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place.. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section.. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases.. There are two main reasons this number is so large and ...
Background The aim of this retrospective study was to determine whether progesteron receptor (PgR) status have an influence on the prognosis of estrogen receptor positive (ER+)/HER2-negative breast carcinoma (BC).. Methods We retrospectively reviewed the medical files of 1680 operable BC patients (pts) diagnosed between 1996 and 2011 and 456 of whom ER,PgR and HER2 status known were included in this study. Patients were categorized into 2 groups; as group A (ER + /PgR-/HER2-negative) and group B (ER + /PgR + /HER2-negative). Twenty one percent (97 pts) of the pts were in group A.. Results Median follow up was 33.5 (0-177) months. Median age was 54 (21-90) years. Sixty-one percent (278) of the pts had node-positive BC. Sixty percent (276) of the pts were postmenopausal. Eighty percent (365) of the pts received adjuvant chemotherapy (ACT). Adjuvant hormonotherapy (AHT) was recommended to nearly all patients (mostly tamoxifen). Pts in group A had significantly higher lymph node positive disease as ...
Triple-negative (TN) breast cancer is an aggressive subtype of breast cancer associated with a unique set of epidemiologic and genetic risk factors. We conducted a two-stage genome-wide association study of TN breast cancer (stage 1: 1529 TN cases, 3399 controls; stage 2: 2148 cases, 1309 controls) to identify loci that influence TN breast cancer risk. Variants in the 19p13.1 and PTHLH loci showed genome-wide significant associations (P , 5 × 10(-) (8)) in stage 1 and 2 combined. Results also suggested a substantial enrichment of significantly associated variants among the single nucleotide polymorphisms (SNPs) analyzed in stage 2. Variants from 25 of 74 known breast cancer susceptibility loci were also associated with risk of TN breast cancer (P , 0.05). Associations with TN breast cancer were confirmed for 10 loci (LGR6, MDM4, CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and we identified associations with TN breast cancer for 15 additional breast cancer loci (P , 0.05: ...
BACKGROUND: Adjuvant trastuzumab has been routinely used in HER2-positive operable breast cancer patients. Prognostic factors remain to be well characterized in these patients and might correlate with primary and/or acquired resistance to trastuzumab.. PATIENTS AND METHODS: The study subjects were 78 HER2-positive operable breast cancer patients treated with adjuvant chemotherapy followed by 1-year trastuzumab between 2005 and 2010 in our institute. All breast tumors showed a HercepTest score of 3+ or that of 2+ and positive fluorescence in situ hybridization. Expression levels of HER1, phosphorylated HER2 (pY1248), HER3, HER4, and p53 were assessed by immunohistochemistry. Prognostic factors were investigated with univariate and multivariate analyses using the Kaplan-Meier/log-rank test and Cox proportional hazards model, respectively.. RESULTS: The median age and follow-up period of the patients were 54 years and 39 months, respectively. The mean tumor size was 2.1 cm and the node-positive ...
Physical activity after breast cancer diagnosis has been linked with prolonged survival and improved quality of life, but most participants in a large breast cancer study did not meet national physical activity guidelines after they were diagnosed. Moreover, African-American women were less likely to meet the guidelines than were White women.. Published online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings indicate that efforts to promote physical activity in breast cancer patients may need to be significantly enhanced.. The study, Racial differences in physical activity among breast cancer survivors: implications for breast cancer care, was led by Ms. Brionna Hair, epidemiology doctoral student at the University of North Carolina Gillings School of Global Public Health.. The U.S. Department of Health and Human Services and the American Cancer Society recommend that adults engage weekly in at least 150 minutes of moderate-intensity physical activity or 75 ...
Introduction: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. So far, these epigenetic contributions to sporadic breast cancer subtypes have not been well characterized, and only a limited understanding exists of the epigenetic mechanisms affected in those particular breast cancer subtypes. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes. Methods: By using a microarray approach, we analyzed DNA methylation in regulatory regions of 806 cancer-related genes in 28 breast cancer paired samples. We subsequently performed substantial technical and biologic validation by pyrosequencing, investigating the top qualifying 19 CpG regions in independent cohorts encompassing 47 basal-like, 44 ERBB2+ overexpressing, 48 ...
Background: We aimed to estimate the effect of alcohol consumption on breast cancer risk and to test whether overweight and obesity modifies this association. Methods: We included in the analysis 45,233 women enrolled in the Swedish Womens Lifestyle and Health study between 1991 and 1992. Participants were followed for occurrence of breast cancer and death until December 2009. Poisson regression models were used, and analyses were done for overall breast cancer and for estrogen receptor positive or negative (ER+, ER-) and progesterone receptor positive and negative (PR+, PR-) tumors separately. Results: A total of 1,385 breast cancer cases were ascertained during the follow-up period. Overall, we found no statistically significant association between alcohol intake and breast cancer risk after adjustment for confounding, with an estimated relative risk (RR) of 1.01 (95 % CI: 0.98-1.04) for an increment in alcohol consumption of 5 g/day. A statistically significant elevated breast cancer risk ...
The authors retrospectively examined the contralateral prophylactic mastectomy (CPM) rate among 100 women with ductal carcinoma in situ who are BRCA negative. Of 100 women with ductal carcinoma in situ, 31 elected contralateral prophylactic mastectomy (CPM). Factors associated with increased likelihood of undergoing contralateral prophylactic mastectomy (CPM) among this cohort were: family history of ovarian cancer, marital status, reconstruction, mastectomy of the affected breast, and tamoxifen use.. Keywords: contralateral prophylactic mastectomy, BRCA negative ...
Scientists at the British Columbia Cancer Agency and University of British Columbia have identified new breast cancer genes. This is a discovery that may change the way breast cancer is diagnosed, as well the way it is treated. - Identification of New Breast Cancer Genes - Breast Cancer at BellaOnline
TY - JOUR. T1 - Longitudinal MRI Evaluation of Intracranial Development and Vascular Characteristics of Breast Cancer Brain Metastases in a Mouse Model. AU - Zhou, Heling. AU - Chen, Min. AU - Zhao, Dawen. PY - 2013/4/29. Y1 - 2013/4/29. N2 - Longitudinal MRI was applied to monitor intracranial initiation and development of brain metastases and assess tumor vascular volume and permeability in a mouse model of breast cancer brain metastases. Using a 9.4T system, high resolution anatomic MRI and dynamic susceptibility contrast (DSC) perfusion MRI were acquired at different time points after an intracardiac injection of brain-tropic breast cancer MDA-MB231BR-EGFP cells. Three weeks post injection, multifocal brain metastases were first observed with hyperintensity on T2-weighted images, but isointensity on T1-weighted post contrast images, indicating that blood-tumor-barrier (BTB) at early stage of brain metastases was impermeable. Follow-up MRI revealed intracranial tumor growth and increased ...
Contralateral prophylactic mastectomy: current perspectives Katharine Yao,1 Mark Sisco,2 Isabelle Bedrosian3 1Division of Surgical Oncology, Department of Surgery, 2Division of Plastic Surgery, Department of Surgery, NorthShore University HealthSystem, Evanston, IL, 3Department of Surgery, MD Anderson Cancer Center, Houston, TX, USA Abstract: There has been an increasing trend in the use of contralateral prophylactic mastectomy (CPM) in the United States among women diagnosed with unilateral breast cancer, particularly young women. Approximately one-third of women ,40 years old are undergoing CPM in the US. Most studies have shown that the CPM trend is mainly patient-driven, which reflects a changing environment for newly diagnosed breast cancer patients. The most common reason that women choose CPM is based on misperceptions about CPM’s effect on survival and overestimation of their contralateral breast cancer (CBC) risk. No prospective studies have shown survival benefit to CPM, and
The practice of contralateral prophylactic mastectomy (CPM) has increased in woman with unilateral breast cancer. This highly invasive approach to the management of breast cancer has been done without hard evidence that it conveys a survival benefit. Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis by Pamela R. Portschy, Karen M. Kuntz, and Todd M. Tuttle just published in the Journal of the National Cancer Institute examines survival outcomes in women with and without CPM. The study excluded women with BRCA mutations. These mutations greatly increase the risk of getting breast, ovarian, and other cancers.. Women choose to have this procedure because of the fear of getting the disease in the remaining breast, though this likelihood is much less common than most patients suppose. Obviously this treatment is only performed on patients who have already had a mastectomy. If the cancer had been treated with any modality short of mastectomy CPM would not be a ...
Background: Metastasis is important in survival and the quality of life of female breast cancer patients. This study was run in order to investigate metastasis and its related factors in female breast cancer patients in Kerman province from 2005 to 2015. The aim of this study was to investigate the factors associated with secondary metastasis in female breast cancer patients in the largest province of Iran (Kerman). Materials and Methods: In this case-control study, medical records of women diagnosed with breast cancer between the years of 2005 to 2015 were studied. Among them, 200 breast cancer patients with secondary metastasis were randomly selected as cases and 400 patients without metastasis were selected as the control group. Backward logistic regression, chi-square test, t-test and Mann-Whitney-U test were performed for comparing the two groups in SPSS 22. Results: Disease stage at diagnosis was significantly associated with secondary metastasis (p|0.001). Female patients with stage III breast
Triple negative breast cancers are defined by the lack of targeted therapy available for women with this type of breast cancer. Where women with hormone positive breast cancers can benefit from hormone therapies, like tamoxifen and aromatase inhibitors, and HER2+ breast cancers benefit from targeted therapies like Herceptin and Bevacizumab, treatment for triple negative breast cancers are limited to the slash/burn/poison of surgery/radiation/chemotherapy. Where once women with HER2+ breast cancers were considered to have the worst outcomes since the development of targeted HER2 therapies, the terrible distinction of worst outcomes of breast cancer subtypes now goes to triple negative disease. Here are some updates on triple negative disease from this years San Antonio Breast Cancer Symposium.. Carboplatin. Two trials reported on Wednesday afternoon looked at carboplatin to treat triple negative breast cancer. Prior data has not established a role for this highly toxic treatment in early stage ...
A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the benefits of contralateral prophylactic mastectomy.1 (Earlier studies about perceptions of contralateral breast cancer and contralateral prophylactic mastectomy are referenced in the current study.). The less than 1% survival benefit was found among all subgroups studied-by age, estrogen receptor status, and cancer stage-although contralateral prophylactic mastectomy was more beneficial among younger women, those with stage I disease, and those with estrogen receptor-negative breast cancer, according to the report, published in the Journal of the National Cancer Institute.1 The stated aim of the study was to provide projected long-term survival information by using a stimulated Markov model for ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
SAN DIEGO, Dec. 7, 2017 /PRNewswire/ - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer Symposium (SABCS) on December 7th, from 5:00 - 7:00 PM CST, in San Antonio, Texas.. Trovagenes poster entitled, Sensitivity of Triple Negative Breast Cancer Cell Lines to PCM-075, a Highly Selective Polo-like Kinase 1 Inhibitor, presents the preclinical analysis of 40 cancer cell lines and demonstrates that triple negative breast cancer (TNBC) cell lines are 20-fold more sensitive to PCM-075 than estrogen receptor positive (ER+) breast cancer cells lines.. Polo-like Kinase 1 (PLK1) is known to be over-expressed in many hematologic and solid tumor cancers, including breast cancer. PLK1 inhibition by PCM-075 induces ...
Abstract: Increasing numbers of women with breast cancer are electing for contralateral prophylactic mastectomy (CPM) to reduce the risk of developing contralateral breast cancer. The objective of this study was to identify factors that may affect a patients decision to undergo CPM. We identified 2,504 women with stage 0 to III unilateral primary breast cancer who underwent breast surgery at our institution from January 2000 to August 2006 from a prospectively maintained database. We did logistic regression analyses to determine which factors were associated with undergoing CPM. Of 2,504 breast cancer patients, 1,223 (48.8%) underwent total mastectomy. Of the 1,223 patients who underwent mastectomy, 284 (23.2%) underwent immediate or delayed CPM. There were 33 patients (1.3%) who had genetic testing before the surgery, with the use of testing increasing in the latter years of the study (0.1% in 2000-2002 versus 2.0% in 2003-2006; P , 0.0001). Multivariable analysis revealed several factors that ...
Breast cancer is the most common form of cancer and the second leading cause of malignancy-associated death in women worldwide. Estrogens are the main sex hormones in women. They are essential for the development and function of normal breast mammary glands; however, prolonged exposure to estrogens increases the risk of breast cancer development and progression. Approximately two-thirds of all breast cancer patients are positive for estrogen receptor (ER), but only 50% of those cases can benefit from antiestrogen therapy.. In this thesis we investigated the effects of estrogen, diet modification, and anti-estrogen drugs on several immune modulators in normal human breast tissue. We used the microdialysis technique to sample the immune modulators in situ in normal human breast tissue, in malignant breast tissue, and in tumor tissue from both the immune competent mice with murine breast cancer and immune deficient mice bearing human breast tumors. Furthermore, we also used ex vivo culture of ...
Overexpression of the oncogene HER2/neu (c-erbB-2) occurs in up to 30% of breast cancers and is correlated with reduced survival, especially in node-positive disease. The aim of this study was to identify genes associated with the aggressive phenotype of HER2/neu-positive breast cancer cells using cDNA microarrays. RNA was extracted from three HER2/neu-positive and three HER2/neu-negative breast cancer cell lines. Pooled RNA was hybridized in duplicate to the breast specific microarray filters from Research Genetics containing 5184 unique cDNAs. Subsequently, a similar comparison was performed for pooled RNAs from 10 node-positive, ER-positive invasive ductal carcinomas, half of which were HER2/neu overexpressers. In HER2/neu overexpressing breast cancer cell lines, 90 (1.7%) genes were up-regulated and 46 (0.9%) were down-regulated, compared to cell lines with low HER2/neu protein levels. In contrast, in HER2/neu overexpressing primary breast cancers, more genes were down-regulated (N = 132, 2.5%) than
TY - JOUR. T1 - Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231. AU - De Blasio, Anna. AU - Di Fiore, Riccardo. AU - Morreale, Marco. AU - Carlisi, Daniela. AU - Drago-Ferrante, Rosa. AU - Montalbano, Mauro. AU - Scerri, Christian. AU - Tesoriere, Giovanni. AU - Vento, Renza. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Triple-negative breast cancer (TNBC) is a clinically aggressive form of breast cancer that is unresponsive to endocrine agents or trastuzumab. TNBC accounts for ∼10-20% of all breast cancer cases and represents the form with the poorest prognosis. Patients with TNBC are at higher risk of early recurrence, mainly in the lungs, brain and soft tissue, therefore, there is an urgent need for new therapies. The present study was carried out in MDA-MB-231 cells, where we assessed the role of caspase-8 (casp-8), a critical effector of death receptors, also involved in non-apoptotic functions. Analysis of casp-8 mRNA and protein levels indicated that they were ...
Pregnancy is safe for women with estrogen receptor positive breast cancerSome people have basic questions about how pregnancy happens. Some may have questions about avoiding a pregnancy
Breast cancer brain metastases (BCBM) develop in about 20-30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p | 0.05 and fold change (FC) | 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM. The top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1,
TY - JOUR. T1 - Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab. T2 - A multicenter retrospective observational study (JBCRG-C03 study). AU - Takada, M.. AU - Ishiguro, H.. AU - Nagai, S.. AU - Ohtani, S.. AU - Kawabata, H.. AU - Yanagita, Y.. AU - Hozumi, Y.. AU - Shimizu, C.. AU - Takao, S.. AU - Sato, N.. AU - Kosaka, Y.. AU - Sagara, Y.. AU - Iwata, H.. AU - Ohno, S.. AU - Kuroi, K.. AU - Masuda, N.. AU - Yamashiro, H.. AU - Sugimoto, M.. AU - Kondo, M.. AU - Naito, Yasuhiro. AU - Sasano, H.. AU - Inamoto, T.. AU - Morita, S.. AU - Toi, M.. PY - 2014. Y1 - 2014. N2 - We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using ...
Circulating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is critical to identifying the key drivers of cancer metastasis and devising therapeutic approaches. However, the molecular characterization of CTCs is difficult to achieve because their isolation is a major technological challenge. CTCs from two triple negative breast cancer patients were enriched using CellSearch and single cells selected by DEPArray™. A TP53 R110 fs*13 mutation identified by next generation sequencing in the breast and chest skin biopsies of both patients was studied in single CTCs. From 6 single CTC isolated from one patient, 1 CTC had TP53 R110 delC, 1 CTC showed the TP53 R110 delG mutation, and the remaining 4 single CTCs showed the wild type p53 sequence; a pool of 14 CTCs isolated from the same patient also showed TP53 R110 delC mutation. In the tumor breast tissue
Purpose: Breast conservation has been shown to have similar mortality rates as compared to mastectomy. We hypothesized that variables involving the patient, tumor and surgeon influence the treatment a patient may choose. Methods: Retrospective review of a prospectively maintained database of all patients who underwent surgical treatment for breast cancer between 2000 and 2009 was performed. Multivariate logistic regression models were used to compare characteristics associated with breast conservation therapy (BCT) and contralateral prophylactic mastectomy (CPM). Results: Of 1826 patients, 806 underwent BCT and 207 underwent CPM. Exclusion criteria included unilateral mastectomy (n = 761), bilateral disease, stage IV disease, and incomplete records. Larger average tumor size and number of lymph nodes examined were associated with CPM (both p | 0.0001). There were higher odds of patients who underwent CPM when younger than 40 (OR = 3.1), less than 50 years of age (OR = 2.5), with a history of breast
Estrogen receptor-negative (ER(-)) breast cancers have limited treatment options and are associated with earlier relapses. Because glucocorticoid receptor (GR) signaling initiates antiapoptotic pathways in ER(-) breast cancer cells, we hypothesized that activation of these pathways might be associated with poor prognosis in ER(-) disease. Here we report findings from a genome-wide study of GR transcriptional targets in a premalignant ER(-) cell line model of early breast cancer (MCF10A-Myc) and in primary early-stage ER(-) human tumors. Chromatin immunoprecipitation with massively parallel sequencing (ChIP-seq) coupled to time-course expression profiling led us to identify epithelial-to-mesenchymal transition (EMT) pathways as an important aspect associated with GR activation. We validated these findings by carrying out a meta-analysis of primary breast tumor gene expression from 1,378 early-stage breast cancer patients with long-term clinical follow-up, confirming that high levels of GR expression
Triple negative breasts cancer (TNBC) gets the poorest prognosis of most types of breasts malignancy and currently lacks effective targeted therapy. for TNBC treatment. Intro Triple negative breasts cancer (TNBC) makes up about ~15C20% of breasts cancer occurrence [1]. These tumors are extremely aggressive, metastatic, and also have the most severe short-term prognosis among all breasts malignancy types [1,2]. Unlike estrogen receptor positive (ER+) breasts cancer, which may be successfully treated with aromatase inhibitors, tamoxifen or various other selective estrogen receptor modulators (SERMs), there is absolutely no targeted therapy presently accepted for TNBC. Chemotherapy and medical procedures will be the current standard-of-care (SOC) for TNBC [1,3,4]. Aside from the severe unwanted effects connected with chemotherapies, the choice pressure induced by non-specific chemotherapy drugs as well as the advancement of drug level of resistance also can promote metastasis [5C8]. Surgery of the ...
Specific, high affinity receptors for 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] have been demonstrated in human breast cancer cells. In addition, 1,25-(OH)2D3 has been shown to inhibit replication in some human breast cancer cell lines, although the mechanism(s) of this anti-tumor activity remain undefined. There is currently considerable interest in the role of autocrine growth factors in the control of breast cancer cell proliferation and the effects of steroid hormones on their production, receptor binding, and action. Since the epidermal growth factor (EGF) receptor mediates the effects of both EGF and the autocrine growth factor, alpha-transforming growth factor, we investigated the effect of 1,25-(OH)2D3 on EGF receptor levels in several human breast cancer cell lines. Preincubation of T-47D cells with 1,25-(OH)2D3 for 24 h resulted in a significant concentration-dependent decline in the specific binding of [125I]EGF. The effect was observed when EGF binding was assayed at either 0 or 37 degrees C,
Estrogen receptor and progesterone receptor status are routinely assessed using immunohistochemistry assays to assist in patient prognosis and clinical management. Three commonly utilized autostainer vendors-Dako, Leica and Ventana-provide ready-to-use progesterone receptor assays; however, they have never been directly compared in a single breast cancer cohort. We looked at three immunohistochemical progesterone receptor assays, in addition to original ligand-binding assay results, in a single retrospective, tamoxifen-treated breast cancer cohort to investigate inter- and intra-observer agreement, concordance, prognostic ability and measures of test performance. All immunohistochemical assays utilized the manufacturers specified protocols. Five-year disease-free survival was the endpoint of interest, and multivariate models were adjusted for lymph node status, tumor grade, tumor size and human epidermal growth factor 2 status. All assays showed substantial to almost perfect agreement between the three
TY - JOUR. T1 - Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine. T2 - A retrospective population-based time-dependent cohort study. AU - Yang, Szu Pang. AU - Muo, Chih Hsin. AU - Wang, I. Kuan. AU - Chang, Yen Jung. AU - Lai, Shih Wei. AU - Lee, Cynthia Wei Sheng. AU - Morisky, Donald E.. PY - 2015/12/1. Y1 - 2015/12/1. N2 - Aims: We aimed to examine whether morphine treatment is associated with type 2 diabetes mellitus (T2DM) in female breast cancer patients. Methods: We conducted a retrospective cohort analysis of the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast cancer without T2DM history during the period 2000-2005 were identified, divided into morphine and non-morphine users (8071 and 23,041 patients, respectively), and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were calculated. We used a Cox proportional hazard model with time-dependent exposure ...
Objective To evaluate the value of mammographic findings at predicting the presence of an extensive intraductal component (EIC), a major factor in determining breast conserving surgery Methods A prospective study of 348 consecutive mammograms in patients with stage Ⅰ or Ⅱ breast carcinoma, including infiltrating ductal carcinoma ( n =297), ductal carcinoma in situ (DCIS) associated with small invasive foci ( n =8), mucinous carcinoma ( n =21), and medullary carcinoma ( n =22), was performed to determine the predictive value of mammographic features in evaluating the presence or absence of an EIC Results (1) EIC+ cancers were significantly more likely to show the lesion with microcalcifications in comparing with EIC- cases (66 4% vs 20 4%, χ 2=75 29, P 0 001) In particular, the presence of microcalcifications alone was more common for EIC+ cancers than for EIC- cancers (21 1% vs 2 0%, χ 2=52 56, P 0 001) (2) 54 6% of patients in whom mammograms showed only a
AND MATERIALS: From July 1986 to April 1993 the International Breast Cancer Study Group (IBCSG) Trial VI randomly assigned 1554 pre/perimenopausal node-positive breast cancer patients to receive cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for either three consecutive courses on months 1-3, or six consecutive courses on months 1-6, both with or without reintroduction CMF. IBCSG Trial VII randomly assigned 1266 postmenopausal node-positive breast cancer patients to receive tamoxifen for 5 years, or tamoxifen for 5 years with three early cycles of CMF, both with or without three courses of delayed CMF. Both trials allowed a choice of mastectomy, or breast-conserving surgery plus radiation therapy, and both were stratified by type of surgery. Radiotherapy was delayed until the initial block of CMF was completed; 4 or 7 months after surgery for pre/perimenopausal patients, and 2 or 4 months after surgery for postmenopausal patients. Over both trials, 718 eligible patients elected to ...
TY - JOUR. T1 - I do not even say it - A mixed methods study on breast cancer awareness of omani women. AU - Alkhasawneh, Esra. AU - Siddiqui, Saad T.. AU - Leocadio, Michael. AU - Seshan, Vidya. AU - Al-Farsi, Yahya. AU - Al-Moundhri, Mansour S.. PY - 2016. Y1 - 2016. N2 - Background: The incidence of breast cancer is rising in Oman, and the disease is diagnosed at late stages, when treatment success is limited. Omani women might benefit from better awareness, so that breast cancer can be detected early and treated. This study was conducted to assess Omani womens levels of breast cancer awareness and early detection practice, and explore factors which might influence these levels. Materials and Methods: A mixed methods study was conducted in 2014, including a quantitative survey of 1,372 and a qualitative assessment of 19 Omani women, aged ≥20 years from five Omani governorates using convenient sampling. Demographic information and scores for awareness levels were used in a multivariate ...
Antiestrogens are currently used for treating breast cancer patients who have estrogen receptor-positive tumors. However, patients with advanced disease will eventually develop resistance to the drugs. Therefore, compounds effective on antiestrogen-resistant tumors will be of great importance for future breast cancer treatment. In this study, we have investigated the effect of the chemotherapeutic compound cisplatin using a panel of antiestrogen-resistant breast cancer cell lines established from the human breast cancer cell line MCF-7. We show that the antiestrogen-resistant cells are significantly more sensitive to cisplatin-induced cell death than antiestrogen-sensitive MCF-7 cells and we show that cisplatin induces cell death by activating both the caspase and lysosomal death pathways. The antiestrogen-resistant cell lines express lower levels of antiapoptotic Bcl-2 protein compared with parental MCF-7 cells. Our data show that Bcl-2 can protect antiestrogen-resistant breast cancer cells from
There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA-mutated HER2-negative metastatic breast cancer. Using the random-effect model, we calculated summary risk estimates (pooled HR and OR with 95% CI) for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), any grade and grade 3-4 adverse events (AEs), treatment discontinuation rate and time to deterioration in quality of life (QoL). Two RCTs (n=733) were included. As compared with monochemotherapy, single-agent PARPi significantly ...
New life-saving treatments for HER-2 Negative Metastatic Breast Cancer in clinical trial on Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
New life-saving treatments for HER-2 Negative Metastatic Breast Cancer in clinical trial on Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. [email protected] Repository ...
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative metaanalyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995. Methods Information was available on 42 000 women in 78 randomised treatment comparisons (radiotherapy vs no radiotherapy, 23 500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment comparison were identified. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% (?10%, 17 000 women; ?10%, 25 000 women). Findings About three-quarters of the eventual local recurrence risk occurred during the first 5 years. In the comparisons that involved little (?10%) difference in 5-year local recurrence
Cisplatin (Csp) is a recurrently used chemotherapeutic drug but its use is inadequate due to undesirable adverse effects. In search of alternative medicine more attention has been given to phytochemicals. Septilin (Spt), a polyherbal drug and its therapeutic potential is huge but there is a scarcity of studies on its cytotoxic potential on cancer cells. The current study was designed to examine the effects of Spt in combination with Csp on human breast adenocarcinoma (MCF-7) and normal human breast epithelial (MCF-10A) cell lines. Cell viability for Spt treated cells was studied using MTT assay. IC50 value of Csp on MCF-7 cells was found to be 10 µg/mL at 24 h. This dose was further used to study the combined effects of Csp with Spt on MCF-7 and MCF-10A cell lines. Maximum cytotoxicity of Spt on MCF-7 cells was observed at Spt 5 µg/mL. The mechanism of Spt induced cytotoxicity was studied using apoptosis assay. Spt did not show any cytotoxic effects on MCF-10 A normal human breast epithelial ...
Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other ...
Objective: To analyze the implementation of a switching policy of adjuvant aromatase inhibitor (AI) therapy sequentially after tamoxifen in consecutively treated stage I (T1N0M0) hormone receptor (HR)-positive breast cancer (BC) patients. Methods: The records of 279 consecutive HR-positive BC patients diagnosed between 2002 and 2006 and followed at the Soroka Medical Center were reviewed. Results: Two-hundred-seventeen patients who initially received tamoxifen were suitable for switching and 28 received an AI as initial adjuvant treatment. The switch was accomplished in 82.5% of the 217 patients. Those who switched to an AI had a higher proportion of T1c stage than patients eligible who were not switched, but did not differ in age, histologic grade, or having received chemotherapy. Of the 179 patients who switched, 155 (86.6%) completed at least 4.5-5 years of adjuvant tamoxifen/AI therapy. Eighteen patients discontinued AI therapy prematurely because of toxicity. Conclusions: In this stage I BC ...
Trastuzumab has conferred significant clinical benefits in HER-2-positive breast carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridisation (FISH), but appropriate assessment of HER2 status remains subject to considerable debate. Data on the health economic impact of HER-2 test strategies are limited. A life-long Markov state transition model was used to assess costs and effectiveness of HER-2 assay strategies (based on IHC, FISH, both combined or FISH confirmation of IHC2+) for a hypothetical cohort of early breast cancer patients from the perspective of the Swiss health system. We compared clinically relevant strategies of predictive testing and subsequent trastuzumab treatment of HER-2-positive patients only. FISH testing was the most cost-effective strategy with an incremental cost-effectiveness ratio of ?12,245 per additional quality-adjusted life-year (QALY) gained, compared to no trastuzumab treatment. The next best strategy was parallel ...
The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other breast cancers and have fewer treatment options because hormonal ...
The use of ultra-diluted natural products in the management of disease and treatment of cancer has generated a lot of interest and controversy. We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines. We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE). The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis. These effects were accompanied by altered expression of the cell cycle regulatory proteins, including downregulation of phosphorylated Rb and upregulation of the CDK inhibitor p27, which were likely responsible for the cell cycle delay/arrest as well as induction of the apoptotic cascade that manifested in the activation of caspase 7 and cleavage ...